Paul Tudor Jones's BEAM Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 16,207 shares of Beam Therapeutics Inc. (BEAM) worth $449,258, representing 0.00% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in BEAM, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 47,845 shares. Largest reduction occurred in Q4 2021, reducing 46,974 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Beam Therapeutics (BEAM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Beam Therapeutics (BEAM) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +16,207 | New Buy | 16,207 | $27.72 |
| Q3 2025 | -46,378 | Sold Out | 0 | $0.00 |
| Q2 2025 | +46,378 | New Buy | 46,378 | $17.01 |
| Q1 2025 | -16,575 | Sold Out | 0 | $0.00 |
| Q4 2024 | -16,242 | Reduce 49.49% | 16,575 | $24.80 |
| Q3 2024 | -16,205 | Reduce 33.06% | 32,817 | $24.50 |
| Q2 2024 | +1,177 | Add 2.46% | 49,022 | $23.43 |
| Q1 2024 | +47,845 | New Buy | 47,845 | $33.04 |
| Q3 2023 | -6,821 | Sold Out | 0 | $0.00 |
| Q2 2023 | +6,821 | New Buy | 6,821 | $31.93 |
| Q4 2022 | -40,839 | Sold Out | 0 | $0.00 |
| Q3 2022 | +40,839 | New Buy | 40,839 | $47.65 |
| Q2 2022 | -7,518 | Sold Out | 0 | $0.00 |
| Q1 2022 | +7,518 | New Buy | 7,518 | $57.33 |
| Q4 2021 | -46,974 | Sold Out | 0 | $0.00 |
| Q3 2021 | +41,728 | Add 795.43% | 46,974 | $87.01 |
| Q2 2021 | +5,246 | New Buy | 5,246 | $128.67 |
Paul Tudor Jones's Beam Therapeutics Investment FAQs
Paul Tudor Jones first purchased Beam Therapeutics Inc. (BEAM) in Q2 2021, acquiring 5,246 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Beam Therapeutics Inc. (BEAM) for 17 quarters since Q2 2021.
Paul Tudor Jones's largest addition to Beam Therapeutics Inc. (BEAM) was in Q1 2024, adding 47,845 shares worth $1.58 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 16,207 shares of Beam Therapeutics Inc. (BEAM), valued at approximately $449,258.
As of the Q4 2025 filing, Beam Therapeutics Inc. (BEAM) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Beam Therapeutics Inc. (BEAM) was 49,022 shares, as reported at the end of Q2 2024.